JP Morgan Maintains Overweight on United Therapeutics, Lowers Price Target to $695
Benzinga Newsdesk 2 days ago
Analyst RatingsNewsPrice Target
JP Morgan analyst Jessica Fye maintains United Therapeutics (NASDAQ:UTHR) with a Overweight and lowers the price target from $710 to $695.
JP Morgan analyst Jessica Fye maintains United Therapeutics (NASDAQ:UTHR) with a Overweight and lowers the price target from $710 to $695.